|
 |
European BioPharmaceutical Review
|
The words prep, process and polymerics are becoming more and more associated together in the biopharma industry as new macroporous polymeric resins are increasingly used in the final 'polishing' of pharma products. Originally polymeric resins were designed as soft gels like cellulose-based gels with low cross linker contents that shrank and swelled with varying solvent conditions and so were not ideal for HPLC due to their poor pressure stability. These gels are classified as microporous gels. They have completely separate and distinct physical and chemical characteristics compared to macroporous gels. Over the years however, polymeric gels have been grouped together and silica-based gels have remained the media support of choice for reversed phase HPLC.
Advances in polymeric design and the inert characteristics of the support have allowed companies in the biopharma industry to re-examine polymerics as viable, if not better, alternatives to silica-based materials. Here we discuss some of the benefits offered by polymerics, making them a viable and economic chromatographic solution for preparative and process chromatography. Polymeric resin design has long since overcome the problems associated with soft gels such as poor mechanical stability, extreme particle swell or shrinkage with solvent composition, low pressure rating and long runtimes, thus making the process less time-consuming, easier and more reproducible for mass production scale.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
